TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)
Launched by NYCOMED · Feb 15, 2006
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with a diagnosis of lung malignancy with or without metastases may be included in the trial if the entry criteria apply.
About Nycomed
Nycomed is a global pharmaceutical company dedicated to the development and commercialization of innovative medical solutions that enhance patient care. With a strong focus on improving health outcomes, Nycomed specializes in a diverse range of therapeutic areas, including respiratory, gastroenterology, and pain management. Committed to research and development, the company collaborates with healthcare professionals and stakeholders to advance clinical trials that contribute to the understanding and treatment of complex medical conditions. Nycomed’s mission is to deliver high-quality products that meet the evolving needs of patients and healthcare systems worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roskilde, , Denmark
Patients applied
Trial Officials
Nycomed Clinical Trial Operations
Study Chair
Headquarters
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials